Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka
Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-136589 · Präparat HOS-097888
Tenofovir: AUC: ↑ 65% (↑ 59 to ↑ 71) Cmax: ↑ 61% (↑ 51 to ↑ 72) Cmin: ↑ 115% (↑ 105 to ↑ 126) Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations of (400 mg/100 mg q.d.) + AUC: ↔ tenofovir resulting from co Atazanavir/Ritonavir Cmax: ↔ administration of tenofovir disoproxil, (300 mg q.d./100 mg q.d.) + sofosbuvir/velpatasvir and Emtricitabine/Tenofovir disoproxil GS-3310072: atazanavir/ritonavir may increase (200 mg/245 mg q.d.) AUC: ↔ adverse reactions related to tenofovir Cmax: ↔ disoproxil, including renal disorders. Cmin: ↑ 42% (↑ 37 to ↑ 49) The safety of tenofovir disoproxil when used with sofosbuvir/velpatasvir and a Velpatasvir: pharmacokinetic enhancer (e.g. AUC: ↑ 142% (↑ 123 to ↑ 164) ritonavir or cobicistat) has not been Cmax: ↑ 55% (↑ 41 to ↑ 71) established. Cmin: ↑ 301% (↑ 257 to ↑ 350) The combination should be used with Atazanavir: caution with frequent renal monitoring AUC: ↔ (see section 4.4). Cmax: ↔ Cmin: ↑ 39% (↑ 20 to ↑ 61)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-31T12:47:00Z · SHA-256 bff22a935481266901d4c92f1163f09cb1d50edd80ede33ac1750318fed62b8d · Passage cb81b8da21901d216ba1d4dc690145d6918665067b309408d5bc5ba9f515289e · Zeichen 18390–20302 im Abschnitt